Www.flypharmaeurope.com

Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!

Welcome to the spring 2024 issue of Pharmafile! As the weather starts to warm up and spring is finally upon us, the themes of change, growth and rejuvenation are at the forefront of our minds, therefore now seems like the perfect time to consider these themes within the pharma industry.

Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!

Www.pharmafocus.com

Janssen, a J&J company, has announced that the CHMP of the EMA has recommended Rybrevant (amivantamab) in combination with chemotherapy.

Ascendis Pharma has announced that the MHRA has granted marketing authorisation for yorvipath (palopegteriparatide; developed as transcon pth) in GB as a parathyroid hormone (pth) replacement therapy for the treatment of adult patients with chronic hypoparathyroidism.

Roche has announced that the FDA has approved Alecensa (alectinib) for the adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Pfizer has announced that the FDA has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate-to-severe haemophilia b.

Eko Health has announced that the FDA has approved its low ejection fraction (low EF) detection artificial intelligence (AI).

Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene-editing therapies for multiple tissue and cell types.

GSK has announced that the FDA has accepted for review a biologics license application (BLA) for its 5-in-1 meningococcal abcwy (menabcwy) vaccine candidate.